^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    BACON: Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Focus V (anlotinib) • cyclophosphamide • Andewei (benmelstobart)
    2d
    APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (clinicaltrials.gov)
    P2, N=60, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3d
    Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P1 trial
    |
    mitomycin
    6d
    Desmoplastic Small Round Cell Tumor Presenting as Bloody Ascites: A Case Report and Literature Review. (PubMed, Surg Laparosc Endosc Percutan Tech)
    DSRCT, although rare, is noted for aggressiveness and rapid progression and therefore should ideally be considered in the differential diagnosis of bloody ascites in young male patients, even when initial cytology is negative. Early application of diagnostic laparoscopy and biopsy may facilitate timely tissue diagnosis, particularly when imaging mimics peritoneal carcinomatosis.
    Journal
    |
    WT1 (WT1 Transcription Factor)
    7d
    STELLA: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=442, Recruiting, Artios Pharma Ltd | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    gemcitabine • irinotecan • alnodesertib (ART0380)
    8d
    Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (clinicaltrials.gov)
    P1/2, N=22, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    8d
    DUAL-OV-CAR-NK: Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    FOLR1 ( Folate receptor alpha ) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    cyclophosphamide • fludarabine IV
    8d
    MAMMOTH: A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=117, Completed, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jan 2026 | Trial primary completion date: May 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • Platinum resistant
    |
    Zejula (niraparib) • azenosertib (ZN-c3)
    8d
    MiR-19b-3p facilitates colorectal cancer metastasis by mediating the crosstalk between tumor-associated endothelial cells and malignant cells. (PubMed, Front Oncol)
    Our findings reveal that miR-19b-3p orchestrates tumor-endothelial interactions by synchronously promoting EMT and EndMT, thereby driving a pro-metastatic microenvironment. Circulating miR-19b-3p represents a promising biomarker and potential therapeutic target in metastatic colorectal cancer.
    Journal
    |
    CDH1 (Cadherin 1) • SOX9 (SRY-Box Transcription Factor 9) • CDH2 (Cadherin 2) • MIR19B1 (MicroRNA 19b-1) • SMYD3 (SET And MYND Domain Containing 3)
    9d
    FIMBRIMENOP: Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer (clinicaltrials.gov)
    P=N/A, N=1100, Not yet recruiting, Centre Oscar Lambret | Trial completion date: Mar 2065 --> Mar 2071 | Trial primary completion date: Mar 2065 --> Mar 2071
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • RAD51C mutation • RAD51D mutation • BRCA mutation
    9d
    OMNI: Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Catholic University of the Sacred Heart
    New trial
    9d
    A preclinical mouse model mimicking the ovarian cancer-induced estrogen deficiency-depression axis. (PubMed, Animal Model Exp Med)
    The combination of intraperitoneal ovarian cancer modeling, ovariectomy, and chronic stress induction establishes a stable and clinically relevant preclinical model of hypoestrogenic ovarian cancer-related depression, suitable for translational research.
    Preclinical • Journal
    |
    ER (Estrogen receptor)